CRISPR Therapeutics Stock Trades Below Consensus Despite Cash and Approved Drug

Despite possessing $2.4 billion in cash and an approved drug, CRISPR Therapeutics' stock is trading nearly 40% below Wall Street's consensus, raising questions among investors.